SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.
Related Questions
How will Kite's acquisition of Interius BioTherapeutics affect Kite's valuation and short‑term stock price dynamics?
What are the expected synergies and timeline for integrating Interius' in‑vivo CAR platform into Kite's existing pipeline?
What regulatory, financing, and dilution considerations arise from the deal, and how might they impact Kite's risk profile relative to peers?